Mizuho lowered the firm’s price target on Verastem (VSTM) to $14 from $16 primarily due to dilution from an April financing, while keeping an Outperform rating on the shares. The firm notes the company reported Q2 results last week, where key takeaways, in its view, were a revenue beat for recently launched Avmapki Fakzynja Co-pack/AFC; already, reimbursement for AFC use off-label in patients who are KRAS-wild-type; an October review for AFC’s potential inclusion in NCCN guidelines; and all other pipeline programs remaining on track.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Closing Bell Movers: Coherent down 18% as earnings miss
- Verastem Unveils Promising VS-7375 Study Results
- Verastem’s VS-7375 shows efficacy in lung cancer
- Verastem Inc. Earnings Call: Positive Outlook with Key Achievements
- Verastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer?